Total Payments
$58,285
2024 Payments
$2,996
Companies
23
Transactions
226
Medicare Patients
13,176
Medicare Billing
$2.0M
Payment Breakdown by Category
Other$46,590 (79.9%)
Food & Beverage$6,416 (11.0%)
Research$2,639 (4.5%)
Travel$2,403 (4.1%)
Education$237.62 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46,590 | 17 | 79.9% |
| Food and Beverage | $6,416 | 196 | 11.0% |
| Unspecified | $2,639 | 1 | 4.5% |
| Travel and Lodging | $2,403 | 8 | 4.1% |
| Education | $237.62 | 4 | 0.4% |
Payments by Type
General
$55,646
225 transactions
Research
$2,639
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45,880 | 88 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $5,890 | 18 | $0 (2024) |
| Eli Lilly and Company | $2,639 | 1 | $0 (2024) |
| Abbott Laboratories | $1,084 | 19 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $691.00 | 37 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $391.29 | 12 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $300.17 | 9 | $0 (2021) |
| Impulse Dynamics (USA) Inc. | $282.15 | 2 | $0 (2023) |
| Medtronic Vascular, Inc. | $258.82 | 5 | $0 (2019) |
| ABIOMED | $184.08 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,996 | 10 | Eli Lilly and Company ($2,639) |
| 2023 | $857.66 | 26 | Novartis Pharmaceuticals Corporation ($301.56) |
| 2022 | $833.63 | 17 | Impulse Dynamics (USA) Inc. ($128.63) |
| 2021 | $799.72 | 27 | Abbott Laboratories ($189.04) |
| 2020 | $3,051 | 18 | Novartis Pharmaceuticals Corporation ($2,730) |
| 2019 | $36,373 | 53 | Novartis Pharmaceuticals Corporation ($30,525) |
| 2018 | $12,862 | 62 | Novartis Pharmaceuticals Corporation ($11,887) |
| 2017 | $512.05 | 13 | AstraZeneca Pharmaceuticals LP ($228.17) |
All Payment Transactions
226 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/28/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/20/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $26.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.50 | General |
| Category: Cardiovascular | ||||||
| 06/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $113.39 | General |
| Category: Cardiology | ||||||
| 05/29/2024 | Eli Lilly and Company | — | — | In-kind items and services | $2,638.58 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 05/29/2024 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $82.31 | General |
| 03/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.00 | General |
| Category: Cardiovascular | ||||||
| 01/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.96 | General |
| Category: Cardiovascular | ||||||
| 01/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $32.35 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/05/2023 | Impulse Dynamics (USA) Inc. | OPTIMIZER (Device), OPTIMIZER | Food and Beverage | Cash or cash equivalent | $153.52 | General |
| Category: Cardiovascular Device | ||||||
| 12/05/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $27.82 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $25.92 | General |
| 11/03/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $32.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/28/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $27.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/14/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/12/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.83 | General |
| Category: Cardiovascular | ||||||
| 06/21/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $20.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/09/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/19/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/11/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: Cardiovascular | ||||||
| 05/10/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.23 | General |
| Category: Not Applicable | ||||||
| 05/08/2023 | Abbott Laboratories | THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) | Food and Beverage | In-kind items and services | $100.70 | General |
| Category: Heart Failure | ||||||
| 05/03/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $2,639 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 3,304 | 11,785 | $2.9M | $495,113 |
| 2022 | 41 | 3,316 | 6,787 | $2.8M | $476,378 |
| 2021 | 34 | 3,149 | 6,047 | $2.8M | $523,715 |
| 2020 | 41 | 3,407 | 5,781 | $2.9M | $550,140 |
Total Patients
13,176
Total Services
30,400
Medicare Billing
$2.0M
Procedure Codes
159
All Medicare Procedures & Services
159 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 89 | 89 | $364,989 | $110,762 | 30.3% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 89 | 178 | $155,750 | $69,910 | 44.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 329 | 493 | $291,363 | $56,207 | 19.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 192 | 195 | $496,470 | $32,985 | 6.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 101 | 247 | $142,766 | $30,958 | 21.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 126 | 498 | $32,370 | $20,462 | 63.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 263 | 267 | $144,591 | $18,284 | 12.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 93 | 100 | $107,800 | $17,535 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 59 | 104 | $82,264 | $17,463 | 21.2% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 66 | 66 | $236,808 | $16,375 | 6.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 38 | 38 | $153,862 | $14,648 | 9.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 75 | 154 | $62,062 | $12,704 | 20.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $54,660 | $9,558 | 17.5% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 131 | 131 | $109,254 | $8,513 | 7.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $46,453 | $8,377 | 18.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 814 | 965 | $75,270 | $7,786 | 10.3% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 38 | 76 | $18,240 | $6,884 | 37.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 11 | 22 | $33,066 | $4,987 | 15.1% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 40 | 40 | $33,880 | $4,515 | 13.3% |
| 75571 | Ct scan of heart with evaluation of blood vessel calcium | Office | 2023 | 39 | 39 | $15,600 | $3,449 | 22.1% |
| 71275 | Ct scan of blood vessels of chest with contrast | Office | 2023 | 14 | 14 | $42,154 | $3,405 | 8.1% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 13 | 13 | $34,359 | $2,776 | 8.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 193 | 212 | $36,464 | $2,736 | 7.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 20 | 20 | $11,800 | $2,394 | 20.3% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 21 | 21 | $34,545 | $2,357 | 6.8% |
About Dr. Jacob Kelly, MD
Dr. Jacob Kelly, MD is a Cardiovascular Disease healthcare provider based in Anchorage, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1851551949.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacob Kelly, MD has received a total of $58,285 in payments from pharmaceutical and medical device companies, with $2,996 received in 2024. These payments were reported across 226 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($46,590).
As a Medicare-enrolled provider, Kelly has provided services to 13,176 Medicare beneficiaries, totaling 30,400 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 159 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Anchorage, AK
- Active Since 06/11/2008
- Last Updated 01/14/2026
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1851551949
Products in Payments
- ENTRESTO (Drug) $45,519
- ELIQUIS (Drug) $563.41
- LEQVIO (Drug) $361.28
- UPTRAVI (Drug) $359.61
- ONPATTRO (Drug) $345.87
- CardioMEMS HF System (Device) $343.75
- OPSUMIT MACITENTAN (Drug) $254.02
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT (Device) $221.65
- HeartWare HVAD (Device) $220.79
- BRILINTA (Drug) $195.17
- HeartMate 3 Left Ventricular Dev (Device) $185.36
- Impella (Device) $184.08
- CAMZYOS (Drug) $169.78
- OPTIMIZER (Device) $153.52
- Optimizer (Device) $128.63
- HeartMate (Device) $113.75
- Connectivity and Remote care (Device) $108.08
- CARDIOMEMS (Device) $84.41
- VIGILANT (Device) $81.94
- CHANTIX (Drug) $57.31
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Anchorage
Ahmed Abuzaid, Md, MD
Cardiovascular Disease — Payments: $54,900
Cardiovascular Disease $54,900
Steven Compton, M.d, M.D
Cardiovascular Disease — Payments: $50,777
Cardiovascular Disease $50,777
Dr. Suneet Purohit, M.d, M.D
Cardiovascular Disease — Payments: $50,260
Cardiovascular Disease $50,260
Josiah Brown, Md, MD
Cardiovascular Disease — Payments: $11,945
Cardiovascular Disease $11,945
Dr. Carson Webb, Md, MD
Cardiovascular Disease — Payments: $10,560
Cardiovascular Disease $10,560
Krzysztof Balaban, M.d, M.D
Cardiovascular Disease — Payments: $6,202
Cardiovascular Disease $6,202